AVROBIO Investor Relations Material

Latest events

M&A Announcement


M&A Announcement

30 Jan, 2024

Q1 2023

11 May, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from AVROBIO Inc

Access all reports
AVROBIO, Inc. is a clinical-stage biotechnology company specializing in the development of gene therapies using a lentiviral-based platform. These therapies are designed to treat rare diseases with a single dose, and involve modifying hematopoietic stem cells extracted from patients. AVROBIO focuses on a range of genetic disorders, employing its proprietary plato® platform to optimize these therapies. Notable diseases targeted by AVROBIO's gene therapies include Gaucher disease, Pompe disease, cystinosis, and Hunter syndrome, with several treatments in various stages of clinical trials. The company was established in 2015 and is based in Cambridge, Massachusetts. Its shares are listed on the NASDAQ.